This technology introduces a novel class of synthetic genetic polymers, capable of enhancing protein target binding and mimicking antibodies, for therapeutic and diagnostic applications.
The invention introduces a groundbreaking approach to increase the biological stability and binding affinity of XNA (xeno nucleic acid) molecules. By incorporating base modified side chains that mimic amino acid residues, this method enhances the interaction between XNA aptamers and their protein targets, akin to antibody-antigen interactions. This advancement opens new avenues for the development of highly specific and stable therapeutic and diagnostic agents.
Country | Type | Number | Dated | Case |
Patent Cooperation Treaty | Reference for National Filings | WO 2023/009898 | 02/02/2023 | 2021-774 |
Patent Pending